442 related articles for article (PubMed ID: 27439478)
1. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
[TBL] [Abstract][Full Text] [Related]
2. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
3. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
4. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.
Liu Q; Xu C; Kirubakaran S; Zhang X; Hur W; Liu Y; Kwiatkowski NP; Wang J; Westover KD; Gao P; Ercan D; Niepel M; Thoreen CC; Kang SA; Patricelli MP; Wang Y; Tupper T; Altabef A; Kawamura H; Held KD; Chou DM; Elledge SJ; Janne PA; Wong KK; Sabatini DM; Gray NS
Cancer Res; 2013 Apr; 73(8):2574-86. PubMed ID: 23436801
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
[TBL] [Abstract][Full Text] [Related]
7. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
[TBL] [Abstract][Full Text] [Related]
8. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract][Full Text] [Related]
9. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
10. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
11. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
Rewcastle GW; Kolekar S; Buchanan CM; Gamage SA; Giddens AC; Tsang KY; Kendall JD; Singh R; Lee WJ; Smith GC; Han W; Matthews DJ; Denny WA; Shepherd PR; Jamieson SMF
Oncotarget; 2017 Jul; 8(29):47725-47740. PubMed ID: 28537878
[TBL] [Abstract][Full Text] [Related]
12. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
13. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
15. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
16. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Yu P; Laird AD; Du X; Wu J; Won KA; Yamaguchi K; Hsu PP; Qian F; Jaeger CT; Zhang W; Buhr CA; Shen P; Abulafia W; Chen J; Young J; Plonowski A; Yakes FM; Chu F; Lee M; Bentzien F; Lam ST; Dale S; Matthews DJ; Lamb P; Foster P
Mol Cancer Ther; 2014 May; 13(5):1078-91. PubMed ID: 24634413
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
20. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
Xiao Y; Yu Y; Jiang P; Li Y; Wang C; Zhang R
Cell Oncol (Dordr); 2020 Aug; 43(4):669-680. PubMed ID: 32382996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]